Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11923156 | 0.86 | KIF11 (0.54) | ESR1CYP3A4CYP2D6CYP17A1CYP19A1 | |
| SCHEMBL24630680 | 0.82 | ESR1 (0.38) | ESR1FDPSLOXL2CYP3A4ALDH1A1 | |
| SCHEMBL10034521 | 0.81 | ESR1 (0.45) | ESR1CYP3A4ALDH1A1RAB9ATHRA | |
| SCHEMBL6205695 | 0.80 | SLC6A2 (0.60) | FDPSLOXL2CYP3A4ALDH1A1CYP2D6 | |
| SCHEMBL3236715 | 0.80 | FDPS (0.53) | ESR1FDPSLOXL2CYP3A4ALDH1A1 | |
| SCHEMBL8843066 | 0.80 | CYP3A4 (0.46) | FDPSLOXL2CYP3A4ALDH1A1CYP2D6 | |
| SCHEMBL28811776 | 0.80 | FDPS (0.44) | FDPSLOXL2CYP3A4ALDH1A1CYP2D6 | |
| SCHEMBL6685103 | 0.80 | ESR1 (0.74) | ESR1CYP3A4ALDH1A1CYP2D6THRA | |
| SCHEMBL8362815 | 0.78 | BRS3 (0.45) | FDPSLOXL2CYP3A4ALDH1A1CYP2D6 | |
| SCHEMBL13715390 | 0.78 | LOXL2 (0.43) | FDPSLOXL2CYP3A4ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 724 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113896678-A | Method for preparing 2-chloro-4-neopentyl pyridine | 上海凌凯医药科技有限公司 | 2022-01-07 | — | — | CN | claimed |
| CN-112279804-A | Method for preparing 2-chloro-4-neopentyl pyridine | 上海凌凯医药科技有限公司 | 2021-01-29 | — | — | CN | claimed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11858945-B2 | Alkyne-containing antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-11833122-B2 | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2023-12-05 | — | — | US | disclosed |
| US-11820835-B2 | Cyclic tetrapeptide analogs | UNIVERSITY OF KANSAS (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230357164-A1 | NOVEL QUINAZOLINE DERIVATIVE HAVING FLT3 INHIBITORY ACTIVITY, AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2023-11-09 | — | — | US | disclosed |
| US-7160907-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | disclosed |
| EP-1718297-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005070042-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2004043367-A2 | FUSED HETEROCYCLIC COMPOUNDS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-0910568-A4 | SULFINYL HEXOSE DERIVATIVES USEFUL FOR GLYCOSYLATION | UNIV PRINCETON (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-0910568-A1 | SULFINYL HEXOSE DERIVATIVES USEFUL FOR GLYCOSYLATION | PRINCETON UNIVERSITY (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997034906-A1 | SULFINYL HEXOSE DERIVATIVES USEFUL FOR GLYCOSYLATION | PRINCETON UNIVERSITY (US) | 1997-09-25 | — | — | WO | disclosed |
| EP-0528485-A1 | 17Beta-acyl-3-androsta-3,5-dienes as testosterone 5alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1993-02-24 | — | — | EP | disclosed |
| EP-0465142-A1 | 17Beta-acyl-3-carboxy-androsta-3, 5-dienes as testosterone 5alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1992-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | GLUL, GATD3, GLS | ESR1 3472/4885FDPS 600/4885LOXL2 3955/4885 |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | ESR1 4773/4885FDPS 1060/4885LOXL2 4780/4885 |
| US-11820835-B2 | Cyclic tetrapeptide analogs | CALCA, VIP, OPRL1 | ESR1 4552/4885FDPS 1249/4885LOXL2 2555/4885 |
| US-11858945-B2 | Alkyne-containing antiviral agents | ACE, SARS1, ACE2 | ESR1 4821/4885FDPS 1717/4885LOXL2 4142/4885 |
| US-11833122-B2 | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases | KEAP1, GOT2, COL1A1 | ESR1 2994/4885FDPS 613/4885LOXL2 592/4885 |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | UBQLN1, PSMB1, UBQLN2 | ESR1 2085/4885FDPS 2360/4885LOXL2 1052/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | ESR1 767/4885FDPS 4360/4885LOXL2 2605/4885 |
| US-20230357164-A1 | NOVEL QUINAZOLINE DERIVATIVE HAVING FLT3 INHIBITORY ACTIVITY, AND USE THEREOF | FLT3, ABL1, MCL1 | ESR1 4404/4885FDPS 2615/4885LOXL2 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.